Statement: There results from cohort 3 of the primary trial were inconclusive.
Primary_evidence: Outcome Measurement:    Number of Participants With Adverse Events (AEs)   Number of participants with any grade of adverse events (AEs) graded by Common Terminology Criteria for Adverse Events (CTCAE v4.0) to determine the safety and tolerability of Nivolumab and Daratumumab   Time frame: From first dose to 30 days post last dose (up to 34 months) Results 1:    Arm/Group Title: Nivolumab + Daratumumab (TNBC)   Arm/Group Description: Triple-negative breast cancer (TNBC) treated with Triple-negative breast cancer (TNBC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)   Overall Number of Participants Analyzed: 41   Measure Type: Count of Participants   Unit of Measure: Participants  41 100.0% Results 2:    Arm/Group Title: Nivolumab + Daratumumab (NSCLC)   Arm/Group Description: Non-small cell lung cancer (NSCLC) treated with Nivolumab IV 240 mg Q2W (weeks 3 to 24) + Daratumumab IV 16 mg/kg Q1W (weeks 1 to 8), Daratumumab IV 16 mg/kg Q2W (weeks 9-24)   Overall Number of Participants Analyzed: 21   Measure Type: Count of Participants   Unit of Measure: Participants  21 100.0%